New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab (Q37846678)

24 August 2017

1 reference

title

New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab (English)

1 reference

24 August 2017

0 references

2

1 reference

24 August 2017

3

1 reference

24 August 2017

1

Marta Kurzeja

1 reference

24 August 2017

1 April 2011

1 reference

American Journal of Clinical Dermatology

24 August 2017

1 reference

24 August 2017

12

1 reference

24 August 2017

113-125

1 reference

24 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.2165/11538950-000000000-00000

24 August 2017

0 references

cites work

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Interleukin-12 family members and type I interferons in Th17-mediated inflammatory disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

How microorganisms tip the balance between interleukin-12 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B cell lines to stimulate T and NK cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Cytokine gene-mediated immunotherapy: current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

A unique role for IL-23 in promoting cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

IL-12 and IL-23: master regulators of innate and adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

IL-23 promotes tumour incidence and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Transforming growth factor-beta induces development of the T(H)17 lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

IL-23 receptor regulates unconventional IL-17-producing T cells that control bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

IL-21 and TGF-beta are required for differentiation of human T(H)17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Induction, function and regulation of IL-17-producing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Th17/Th1 phenotype in demyelinating disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

New insights into the pathogenesis and genetics of psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Psoriasis--recent advances in understanding its pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Interleukin-12, interleukin-23, and psoriasis: current prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Th17 cells: a new fate for differentiating helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Pathogenesis and therapy of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Th17 cells: a new therapeutic target in inflammatory dermatoses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Th17 cells: a new paradigm for cutaneous inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

IL-23 and T(H)17-mediated inflammation in human allergic contact dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Th17/Tc17 infiltration and associated cytokine gene expression in elicitation phase of allergic contact dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

The clinical role of IL-23p19 in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Ustekinumab: a new option in psoriasis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Long-term efficacy of biologics in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Etanercept: efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Quality-of-life issues in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Psoriatic arthritis: genetic susceptibility and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Immune regulation in psoriasis and psoriatic arthritis--recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Ustekinumab for psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

A protective and agonistic function of IL-12p40 in mycobacterial infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Mycobacterium bovis BCG-itis and cervical lymphadenitis due to Salmonella enteritidis in a patient with complete interleukin-12/-23 receptor beta1 deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Bacille Calmette-Guérin infection and disease with fatal outcome associated with a point mutation in the interleukin-12/interleukin-23 receptor beta-1 chain in two Mexican families.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

New biologics for psoriasis and psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538950-000000000-00000

10.2165/11538950-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

PubMed ID

21348542

Dimensions Publication ID

24 August 2017

0 references

1 reference

PubMed ID

21348542